Zirconium-89 Labelled Vartumab NCT06645808 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Early Phase 1

Clinical phase

Recruiting

Recruitment status

not reported

Planned enrollment

2026-08-01

Primary-completion proxy

Executive view

NCT06645808 evaluates Zirconium-89 Labelled Vartumab in Recurrent Colon Cancer. The disclosed sponsor is Var2 Pharmaceutical, the design is Interventional, and the geographic footprint is Netherlands. The first listed primary endpoint is Biodistribution and pharmacokinetics of the radiolabeled IMP, assessed over Day 1, 2, and 4 after dosing.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06645808 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Recurrent Colon Cancer landscape. Drug & Asset MCP drug_fetch was queried for Zirconium-89 Labelled Vartumab, while Company & Deal Intelligence MCP organization_fetch was queried for Var2 Pharmaceutical.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT06645808	Zirconium-89 Labelled Vartumab	Early Phase 1 / Recruiting	Var2 Pharmaceutical	Netherlands	Biodistribution and pharmacokinetics of the radiolabeled IMP Day 1, 2, and 4 after dosing	2026-08-01
NCT06703255	Temozolomide	Phase 1/2 / Recruiting	Hangzhou Hansi Biological Pharmaceutical Co., Ltd.	China	Part I: Number of participants experiencing Adverse Events (AEs) All AEs up to 28(±7)days after the last dose of study treatment	2026-12-31
NCT06691308	WL-276 (Imunopharm)	Early Phase 1 / Not yet recruiting	Beijing Imunopharm Technology Co., Ltd.	Geography not reported	Evaluate the safety（Adverse event incidence rate、Incidence rate of abnormal laboratory test results） and tolerability（D… Within 28 days after infusion	2027-05-31
NCT06687681	Allogenic NK cell(Kian Immune Cell Company)	Phase 2 / Recruiting	Kian immune Cell Company	Iran	To measure tumor response after infusion of intrathecal NK cells From enrollment to the end of treatment at 12 months	2025-11-25
NCT06672575	Ivonescimab	Phase 1/2 / Recruiting	The University of Texas MD Anderson Cancer Center	United States	Safety and Adverse Events (AEs) Through study completion; an average of 1 year	2028-01-31

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT06645808 is a Early Phase 1, recruiting study with not reported planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment.

The primary endpoint is “Biodistribution and pharmacokinetics of the radiolabeled IMP” over “Day 1, 2, and 4 after dosing.” The retrieved endpoint description is: Biodistribution and pharmacokinetics of the IMP are defined by the amount of IMP that is taken up per target organ or tissue over time. The radioactive dose absorbed per target organ or tissue over time is determined using whole-body PET/CT imaging at various time points post-injection. In addition, blood samples will be taken at various time points post-injection to determine IMP plasma level concentrations. The ICRP 89 values will be used to calculate the effective dose in each organ. Descriptive statistics of absorbed doses to target organs and tissues specified will be tabulated. The blood concentrations wil….

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Recurrent Colon Cancer. These records do not establish direct evidence for NCT06645808 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Zirconium-89 Labelled Vartumab is indexed as Diagnostic radiopharmaceuticals with target not reported biology and a global stage of Early Phase 1. The asset profile lists Var2 Pharmaceutical as an originator or developer.

Var2 Pharmaceutical is indexed in an unreported country with the website https://var2pharmaceuticals.com. VAR2 Pharmaceuticals develops rVAR2-based cancer targets for drug conjugates, imaging, and oncofetal chondroitin sulfate capture assays. The record lists 7 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Zirconium-89 Labelled Vartumab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT06645808
Protocol source: https://clinicaltrials.gov/study/NCT06645808
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.

Zirconium-89 Labelled Vartumab in Recurrent Colon Cancer is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Biodistribution and pharmacokinetics of the radiolabeled IMP and 2026-08-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP